> top > docs > PMC:7784786 > spans > 1013-1930 > annotations

PMC:7784786 / 1013-1930 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
60 25-33 Species denotes patients Tax:9606
61 168-178 Species denotes SARS-COV-2 Tax:2697049
62 521-529 Species denotes patients Tax:9606
63 653-661 Species denotes patients Tax:9606
64 680-688 Species denotes patients Tax:9606
65 180-190 Chemical denotes Itolizumab MESH:C000597346
66 543-553 Chemical denotes itolizumab MESH:C000597346
67 603-613 Chemical denotes Itolizumab MESH:C000597346
68 16-24 Disease denotes COVID-19 MESH:C000657245
69 35-47 Disease denotes inflammation MESH:D007249
70 104-116 Disease denotes inflammation MESH:D007249
71 348-357 Disease denotes psoriasis MESH:D011565
72 406-418 Disease denotes inflammation MESH:D007249
73 497-511 Disease denotes critically ill MESH:D016638
74 512-520 Disease denotes COVID-19 MESH:C000657245
75 633-645 Disease denotes inflammation MESH:D007249
76 873-881 Disease denotes COVID-19 MESH:C000657245
77 907-916 Disease denotes mortality MESH:D003643

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T4 348-357 Phenotype denotes psoriasis http://purl.obolibrary.org/obo/HP_0003765

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T11 0-12 Sentence denotes Lay abstract
T12 13-98 Sentence denotes In COVID-19 patients, inflammation is associated with the progression of the disease.
T13 99-179 Sentence denotes This inflammation comes from immune system activation in response to SARS-COV-2.
T14 180-258 Sentence denotes Itolizumab is an antibody that recognizes a protein expressed in immune cells.
T15 259-358 Sentence denotes The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis.
T16 359-448 Sentence denotes Its effect is associated with the reduction of inflammation and immune system activation.
T17 449-602 Sentence denotes Here, we report the outcome of three severe and critically ill COVID-19 patients treated with itolizumab as part of an expanded access clinical protocol.
T18 603-662 Sentence denotes Itolizumab was able to reduce inflammation in all patients.
T19 663-762 Sentence denotes Two of the three patients showed respiratory and radiological improvement and were fully recovered.
T20 763-917 Sentence denotes We hypothesize this anti-inflammatory therapy in addition to antiviral and anticoagulant therapy could reduce COVID-19 associated morbidity and mortality.